Bending of a vertical cannula without alarm during insulin pump therapy as a cause of unexpected hyperglycemia: A Japanese issue?

نویسندگان

  • Kaori Kuroda
  • Yumie Takeshita
  • Shuichi Kaneko
  • Toshinari Takamura
چکیده

Currently, two types of cannula are available for Medtronic insulin pump therapy: the vertical Quick-set cannula (Medtronic plc, Dublin, Ireland) and the 30-degree angle Silhouette cannula (Medtronic plc). However, it has not been established which cannula should be used in specific patients. Here, we present two Japanese patients with type 1 diabetes who experienced unexpected episodes of hyperglycemia caused by bending of the vertical cannula during insulin pump therapy. Case 1: An 84-year-old Japanese woman (body mass index 18.7 kg/m) who had fulminant type 1 diabetes caused by drug-induced hypersensitivity syndrome was admitted to Kanazawa University Hospital, Kanazawa, Ishikawa, Japan, because of repeated hyperand hypoglycemic episodes. Her serum and urinary C-peptide were undetectable. We started a continuous subcutaneous insulin infusion (CSII) for better glycemic control. Initially, she used a 9-mm long Quick-set cannula with the infusion set. However, she experienced several episodes of unexpected hyperglycemia caused by bending of the cannula tip and agglutination, even after switching to a 6-mm long Quick-set cannula (Figure 1). Therefore, she switched to a 13-mm long Silhouette cannula inserted at a 30° angle. Subsequently, she did not experience the hyperglycemic episodes caused by obstruction of the cannula. Case 2: A 57-year-old Japanese man (body mass index 21.3 kg/m) who had had type 1 diabetes for 7 years was admitted to our hospital for control of brittle diabetes. His blood glucose had increased recently, and he had experienced some hypoglycemic episodes. He started CSII, using a 9-mm long Quickset cannula. He experienced some unexpected hyperglycemic episodes, without the insulin pump triggering an alarm, caused by cannula bending, which disappeared after switching to the Silhouette cannula. The two patients experienced a total of eight episodes of hyperglycemia. Of these, we recognized a bent cannula in six episodes (one with intracannula agglutination), and a normal cannula appearance in two episodes. Insertion failure or extended indwelling of the cannula alone do not explain the cannula problem, because four of the eight hyperglycemic episodes occurred 24– 72 h after cannula insertion, unlike previous observations that most catheter problems start on day 3. We speculate that the vertical cannula tip reached the abdominal wall and bent during use because both of our patients were thin (skinfold thickness 8 mm in case 1 and 10 mm in case 2). Although the 6-mm long cannula was shorter than the skinfold thickness in case 1, there is a difference between the real skinfold thickness on insertion and the thickness on computed tomography. The cannula bends only on reaching abdominal muscle. Elderly people find it difficult to insert vertical cannulas, and they might not have inserted the cannulas adequately. In addition, a warning should be issued regarding the absence of a pump alarm, which occurred in one of the eight episodes. We conclude that a bent vertical cannula tip should be considered to be a cause of unexpected hyperglycemic episodes during CSII therapy, especially in relatively slender people with diabetes. A prospective randomized controlled study comparing the outcomes of 9 mm versus 6 mm and vertical versus horizontal cannulas in type 1 diabetic patients with different body mass indexes, body fat percentages and skinfold thicknesses is necessary to prove our hypothesis. Furthermore, the alarm system of the CSII device should be improved, so that it detects early cannula obstruction to prevent unexpected hyperglycemic episodes.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Allergy to soft cannula of insulin pump in diabetic patient

Insulin pump is a relatively good choice for diabetic patients who require multiple daily injections with wide fluctuations of blood glucose. Patients using insulin pump therapy and still having uncontrolled blood glucose levels for various factors: insulin pump not working properly, insulin instability, insulin autoantibody, insulin allergy, etc. We described a 46-year-old woman with type 2 di...

متن کامل

کارآزمایی بالینی تنظیم قند خون بیماران دیابتی نوع 1 با استفاده از پمپ انسولین

Background: Pump therapy (CSII) is offered as a safe and effective treatment for patients with type 1 Diabetes. We examined the efficacy and safety of continuous subcutaneous Insulin Infusion Therapy for six months as a before-after clinical trial study among type 1 diabetic patients. This is the first survey of this experience in Iranian patients.Methods: We recruited, type 1 diabetic patients...

متن کامل

Insulin Edema in Type 2 Diabetes Mellitus: A Case Report Study

Edema is a rare complication induced by insulin therapy, which is mostly developed after initiation or intensification of insulin treatment in diabetic patients. Edema can either be localized or generalized. Our patient was a 34-year-old woman with type 2 diabetes. She was under treatment with oral agents medication, but recently insulin therapy was initiated for her due to inability to control...

متن کامل

Insulin Infusion Set Use: European Perspectives and Recommendations

Insulin pump users worldwide depend on insulin infusion sets (IISs) for predictable delivery of insulin to the subcutaneous tissue. Yet emerging data indicates that IISs are associated with many pump-related adverse events and may contribute to potentially life-threatening problem of unexplained hyperglycemia. The relative scarcity of published research on IISs to date, the heterogeneity of reg...

متن کامل

“Let the Algorithm Do the Work”: Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients

BACKGROUND A sensor-augmented insulin pump (SAP) using the MiniMed® 640G system with SmartGuard™ technology allows an automatic stop of insulin delivery based on prediction of low glucose levels. Since pediatric patients are particularly prone to hypoglycemia, this device may offer additional protection beyond conventional sensor-augmented therapy. METHODS This prospective, pediatric multicen...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 6  شماره 

صفحات  -

تاریخ انتشار 2015